New tRNA tech aims to rewrite rare disease treatment
Drug Target Review
JUNE 9, 2025
My transition to biotech and rare diseases was deeply personal – my son was diagnosed with Duchenne muscular dystrophy in 2020. “My My transition to biotech and rare diseases was deeply personal – my son was diagnosed with Duchenne muscular dystrophy in 2020,” Michelle explains.
Let's personalize your content